LIPELLA PHARMACEUTICALS INC (LIPO)
US53630L1008 - Common Stock
Taking everything into account, LIPO scores 2 out of 10 in our fundamental rating. LIPO was compared to 564 industry peers in the Biotechnology industry. The financial health of LIPO is average, but there are quite some concerns on its profitability. LIPO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
LIPO had negative earnings in the past year.
In the past year LIPO has reported a negative cash flow from operations.
In the past 5 years LIPO always reported negative net income.
LIPO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LIPO has a Return On Assets of -189.66%. This is amonst the worse of the industry: LIPO underperforms 89.95% of its industry peers.
LIPO has a worse Return On Equity (-243.13%) than 70.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -189.66% | ||
| ROE | -243.13% | ||
| ROIC | N/A |
ROA(3y)-88.49%
ROA(5y)-64.78%
ROE(3y)-111.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for LIPO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LIPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
LIPO has more shares outstanding than it did 1 year ago.
There is no outstanding debt for LIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -8.50, we must say that LIPO is in the distress zone and has some risk of bankruptcy.
LIPO's Altman-Z score of -8.50 is on the low side compared to the rest of the industry. LIPO is outperformed by 71.27% of its industry peers.
LIPO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.5 |
ROIC/WACCN/A
WACC10.63%
2.3 Liquidity
LIPO has a Current Ratio of 4.33. This indicates that LIPO is financially healthy and has no problem in meeting its short term obligations.
LIPO has a Current ratio (4.33) which is comparable to the rest of the industry.
LIPO has a Quick Ratio of 4.33. This indicates that LIPO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.33, LIPO is in line with its industry, outperforming 50.99% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.33 | ||
| Quick Ratio | 4.33 |
3. Growth
3.1 Past
The earnings per share for LIPO have decreased strongly by -257.99% in the last year.
Looking at the last year, LIPO shows a very strong growth in Revenue. The Revenue has grown by 24.04%.
Measured over the past years, LIPO shows a very negative growth in Revenue. The Revenue has been decreasing by -22.39% on average per year.
EPS 1Y (TTM)-257.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-268.37%
Revenue 1Y (TTM)24.04%
Revenue growth 3Y-22.39%
Revenue growth 5YN/A
Sales Q2Q%27.89%
3.2 Future
Based on estimates for the next years, LIPO will show a very negative growth in Earnings Per Share. The EPS will decrease by -42.38% on average per year.
LIPO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y-30.08%
EPS Next 2Y6.69%
EPS Next 3Y-42.38%
EPS Next 5YN/A
Revenue Next Year-17.65%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LIPO. In the last year negative earnings were reported.
Also next year LIPO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as LIPO's earnings are expected to decrease with -42.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.69%
EPS Next 3Y-42.38%
5. Dividend
5.1 Amount
LIPO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIPELLA PHARMACEUTICALS INC
NASDAQ:LIPO (1/3/2025, 8:00:02 PM)
After market: 3.29 +0.12 (+3.79%)3.17
-0.01 (-0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners7.87%
Inst Owner Change-80.24%
Ins Owners35.49%
Ins Owner Change0%
Market Cap3.84M
Analysts82.86
Price Target10.2 (221.77%)
Short Float %5.58%
Short Ratio0.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)400%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-700%
EPS NY rev (1m)0%
EPS NY rev (3m)-1327.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)28.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.56 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.25 | ||
| P/tB | 2.25 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.34
EYN/A
EPS(NY)-5.3
Fwd EYN/A
FCF(TTM)-3.09
FCFYN/A
OCF(TTM)-3.08
OCFYN/A
SpS0.42
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -189.66% | ||
| ROE | -243.13% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-88.49%
ROA(5y)-64.78%
ROE(3y)-111.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.33 | ||
| Quick Ratio | 4.33 | ||
| Altman-Z | -8.5 |
F-Score4
WACC10.63%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-257.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-268.37%
EPS Next Y-30.08%
EPS Next 2Y6.69%
EPS Next 3Y-42.38%
EPS Next 5YN/A
Revenue 1Y (TTM)24.04%
Revenue growth 3Y-22.39%
Revenue growth 5YN/A
Sales Q2Q%27.89%
Revenue Next Year-17.65%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y18.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-72.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.03%
OCF growth 3YN/A
OCF growth 5YN/A